[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xeno Holdings (US), LLC dba ChoironeX\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100646192","phase-1-study-of-choironex-galko-porcine-thymokidney-xenotransplantation-in-end-stage-renal-disease-100646192",false,"NCT07696962","Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease","Phase 1 Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease","Inclusion Criteria\n\n* ESRD receiving hemodialysis or peritoneal dialysis for ≥6 months\n* Eligible for kidney transplantation per site criteria\n* \\\u003C50% likelihood of receiving a standard deceased-donor kidney transplant within 12 months\n* Blood type and immunologic compatibility with study transplant confirmed by testing\n* EBV seropositive\n* Up to date on recommended vaccinations for immunocompromised individuals\n* Willing to use protocol-required contraception\n* Able to provide informed consent and comply with lifelong follow-up\n\nExclusion Criteria:\n\n* Requirement for multi-organ transplantation\n* Living donor available who is ABO-incompatible\n* Kidney disease with high risk of post-transplant recurrence\n* Polycystic kidney disease without prior native nephrectomy\n* Unable or unwilling to comply with study procedures\n* History of non-adherence to medical treatment\n* Identified as vulnerable by psychological assessment\n* Significant uncontrolled psychiatric illness\n* Inadequate social support or caregiver unavailable\u002Funwilling\n* Current drug or alcohol misuse\n* Serious non-renal illness with life expectancy \\\u003C1 year\n* BMI \\\u003C16 or \\>35 kg\u002Fm²\n* Known hypercoagulable disorder\n* Uncontrolled hypertension or hemodynamic instability at enrollment\n* Clinically significant cardiovascular disease, including poorly controlled coronary artery disease, reduced left ventricular function, recent myocardial infarction or cardiac intervention, or clinically significant arrhythmia requiring treatment\n* Serious liver disease or impaired liver function\n* Diabetes mellitus with poor glycemic control (HbA1c \\>10%)\n* Active infection at time of transplantation\n* Positive serology for hepatitis B, hepatitis C, or HIV\n* Current, active, or untreated tuberculosis\n* Malignancy within 5 years prior to enrollment, excluding adequately treated non-melanoma skin cancer\n* Current systemic immunosuppressive therapy (excluding permitted corticosteroids)\n* Participation in another interventional drug trial within 60 days prior to enrollment\n* Pregnant or breastfeeding\n* Known severe hypersensitivity to a required study medication with no acceptable alternative","ALL","18 Years","70 Years",{"count":20,"type":21},4,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to learn if a GalKO Porcine Thymokidney can maintain renal function, without the need for dialysis, after transplantation into adult subjects with End Stage Renal Disease.",[27],"End Stage Renal Disease",[29],"Kidney, Porcine, Xeno-Transplant","NOT_YET_RECRUITING","2026-07-08",{"date":33,"type":34},"2026-07-10","ACTUAL",{"date":36,"type":21},"2026-07-01",{"date":38,"type":21},"2028-09-30",{"name":40,"class":41},"Xeno Holdings (US), LLC dba ChoironeX","INDUSTRY",2,""]